• 1. An approach to 7-aza-1-phosphanorbornane complexes: strain promoted rearrangement of 1-iminylphosphirane complexes and cycloaddition with olefins?
  Yang Xu,Min Wang,Donghui Wei,Rongqiang Tian,Zheng Duan,Fran?ois Mathey Dalton Trans., 2019,48, 5523-5526
• 2. An integrated cathode and solid electrolyte via in situ polymerization with significantly reduced interface resistance?
  Jialiang Yuan,Ran Dong,Yuan Li,Yang Liu,Zhuo Zheng,Yuxia Liu,Yan Sun,Benhe Zhong,Zhenguo Wu,Xiaodong Guo Chem. Commun., 2021,57, 13004-13007
• 3. An atlas of endohedral Sc2S cluster fullerenes?
  Li-Hua Gan,Rui Wu,Jian-Lei Tian,Patrick W. Fowler Phys. Chem. Chem. Phys., 2017,19, 419-425
• 4. An amide probe as a selective Al3+ and Fe3+ sensor inside the HeLa and a549 cell lines: Pictet–Spengler reaction for the rapid detection of tryptophan amino acid?
  Bidyut Kumar Kundu,Rinky Singh,Ritudhwaj Tiwari,Debasis Nayak New J. Chem., 2019,43, 4867-4877
• 5. Acentric and chiral heterometallic inorganic–organic hybrid frameworks mediated by alkali or alkaline earth ions: synthesis and NLO properties
  Huabin Zhang,Shaowu Du CrystEngComm, 2014,16, 4059-4068

Introduction to 2,4-Dibromo-5-(trifluoromethoxy)aniline (CAS No. 1806329-10-1) and Its Emerging Applications in Chemical Biology

2,4-Dibromo-5-(trifluoromethoxy)aniline, identified by the chemical compound code CAS No. 1806329-10-1, is a halogenated aromatic amine featuring a unique structural motif that has garnered significant attention in the field of chemical biology and pharmaceutical research. This compound, characterized by its two bromine substituents at the 2- and 4-positions and a trifluoromethoxy group at the 5-position of the aniline core, exhibits distinct electronic and steric properties that make it a versatile intermediate in synthetic chemistry and a promising candidate for drug discovery initiatives.

The structural configuration of 2,4-Dibromo-5-(trifluoromethoxy)aniline imparts a high degree of reactivity, enabling its participation in various chemical transformations such as nucleophilic aromatic substitution, cross-coupling reactions, and metal-catalyzed functionalizations. These reactions are pivotal in constructing more complex molecular architectures, which are often required for the development of novel therapeutic agents. The presence of both bromine atoms enhances its utility as a dibromo intermediate, facilitating further derivatization into pharmacologically relevant scaffolds.

Recent advancements in medicinal chemistry have highlighted the potential of halogenated anilines like 2,4-Dibromo-5-(trifluoromethoxy)aniline as key building blocks in the synthesis of small-molecule inhibitors targeting various biological pathways. For instance, studies have demonstrated its applicability in generating kinase inhibitors, where the electron-withdrawing nature of the trifluoromethoxy group and the electron-donating effects of the amino group contribute to optimal binding interactions with protein targets.

The trifluoromethoxy substituent is particularly noteworthy for its ability to modulate metabolic stability and binding affinity. In drug design, such functional groups are often incorporated to improve pharmacokinetic profiles, enhance binding to biological receptors, or increase resistance to enzymatic degradation. The dual halogenation at the 2- and 4-positions further enriches the compound’s reactivity profile, allowing for selective modifications that can fine-tune its biological activity.

In the realm of academic research, 2,4-Dibromo-5-(trifluoromethoxy)aniline has been utilized in exploratory studies aimed at understanding structure-activity relationships (SAR) within halogenated aniline derivatives. These investigations have provided valuable insights into how subtle modifications in the substituent pattern can influence receptor binding affinity and selectivity. Such knowledge is instrumental in guiding the rational design of next-generation therapeutic compounds with improved efficacy and reduced side effects.

The compound’s versatility extends to its role as a precursor in material science applications. Halogenated aromatic amines are increasingly being explored for their potential in organic electronics, including light-emitting diodes (OLEDs) and photovoltaic cells. The electron-deficient nature of 2,4-Dibromo-5-(trifluoromethoxy)aniline, coupled with its ability to form stable radicals upon oxidation, makes it a candidate for developing novel organic semiconductors with enhanced charge transport properties.

From a synthetic chemistry perspective, CAS No. 1806329-10-1 serves as a valuable scaffold for generating libraries of diversified compounds through combinatorial chemistry approaches. The ease with which it can be functionalized allows researchers to rapidly explore novel chemical space, accelerating the discovery process for bioactive molecules. This capability is particularly relevant in high-throughput screening campaigns where large numbers of derivatives are synthesized and evaluated for biological activity.

The growing interest in fluorinated compounds has also positioned 2,4-Dibromo-5-(trifluoromethoxy)aniline as an important reagent in fluorine chemistry. Fluoro-substituted molecules often exhibit superior pharmacological properties compared to their non-fluorinated counterparts due to changes in lipophilicity, metabolic stability, and cell membrane permeability. The strategic incorporation of fluorine atoms into drug candidates has become a cornerstone of modern medicinal chemistry.

Emerging research trends indicate that 2,4-Dibromo-5-(trifluoromethoxy)aniline may find utility in developing next-generation antiviral agents. The structural features present in this compound allow it to mimic natural substrates or inhibit key enzymes involved in viral replication cycles. Preliminary studies have suggested its potential efficacy against certain viral strains by disrupting essential metabolic pathways or interfering with host-virus interactions.

The compound’s stability under various reaction conditions makes it an attractive choice for large-scale synthesis operations within pharmaceutical companies and academic laboratories alike. Its compatibility with standard synthetic protocols ensures reproducibility and scalability, which are critical factors in industrial applications where consistency is paramount.

In conclusion,CAS No 1806329-10-1 represents more than just a chemical entity; it embodies the intersection of innovation and practicality in chemical biology research. Its unique structural attributes have positioned it as a cornerstone molecule for developing novel therapeutics across multiple disease areas while also serving as inspiration for new applications in materials science and advanced manufacturing processes.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)